Clinical Trial Search Results
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and
in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open-label Phase IA/IB Study.
in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open-label Phase IA/IB Study.
This study is currently enrolling.
This is a research study to find out if an experimental drug called ONC-392 is safe and effective in cancer patients and how the drug is absorbed and processed in the body of patients with cancer. ONC-392 is an antibody drug th ...
Shanghai Henlius Biotech, Inc. / “A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC)”
This study is currently enrolling.
The purpose of this study is to compare the efficacy of the investigational drug and placebo (an inactive substance) in combination with chemotherapy and concurrent radiotherapy in your disease and collect safety information on ...
SOTERIA - An Open-Label Long-Term Follow-Up Study to Evaluate the Effects of Sotatercept when Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH
This study is currently enrolling.
We are asking you to take part in this study because you are currently in a study with sotatercept and we want to find out if continuing to take sotatercept is safe and effective over a long period of time.
STARZL NETWORK FOR EXCELLENCE IN PEDIATRIC TRANSPLANTATION (snept) to improve the health of pediatric LIVER TRANSPLANT PATIENTS
This study is currently enrolling.
Pediatric liver transplantation has become the standard of care for many children with liver diseases. However, different institutions often treat and manage children with liver transplant in different ways. Currently, there ar ...
StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention among Adolescent and Young Adult Childhood Cancer Survivors
This study is currently enrolling.
The overall goals of this study are: (1) To compare the effect of 2 different physical activity programs on physical activity levels in adolescents and young adults who received and completed treatment for cancer; and (2) To me ...
STML-ELA-022 A Phase 1b/2, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer (ELEVATE)
This study is currently enrolling.
This research study is being done to find out if elacestrant is safe and tolerable when given in combination with one of the following study drugs, approved in the treatment of advanced breast cancer: alpelisib, everolimus, pal ...
STRIKE-PE: A Prospective, Multicenter Study of the Indigo Aspiration System Seeking to Evaluate the Long-Term Safety and Outcomes of Treating Pulmonary Embolism
This study is currently enrolling.
Your study doctor has determined you have or have had a pulmonary embolism (PE). A PE is a blood clot in an artery or arteries in your lung. A clot can be life threatening if immediate action is not taken to resolve it. At this ...
TARGET-NASH: A 5-year Longitudinal Observational Study of Patients with Nonalcoholic Fatty Liver or Nonalcoholic Steatohepatitis
This study is currently enrolling.
TARGET-NASH is a longitudinal observational cohort study of patients being managed for NASH or NAFL in clinical practice. TARGET-NASH will create a carefully maintained, actively monitored research registry of patients with NAF ...
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
This study is currently enrolling.
This study is being done to answer the following question: Is the combination of T-DM1 and a newer drug tucatinib, better than usual treatment with T-DM1 alone at preventing your cancer from returning? We are doing this study b ...